1. Home
  2. RLMD vs BREA Comparison

RLMD vs BREA Comparison

Compare RLMD & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • BREA
  • Stock Information
  • Founded
  • RLMD 2004
  • BREA 2022
  • Country
  • RLMD United States
  • BREA Ireland
  • Employees
  • RLMD N/A
  • BREA N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • BREA Services-Misc. Amusement & Recreation
  • Sector
  • RLMD Health Care
  • BREA Consumer Discretionary
  • Exchange
  • RLMD Nasdaq
  • BREA Nasdaq
  • Market Cap
  • RLMD 11.5M
  • BREA 9.4M
  • IPO Year
  • RLMD N/A
  • BREA 2023
  • Fundamental
  • Price
  • RLMD $0.40
  • BREA $0.66
  • Analyst Decision
  • RLMD Hold
  • BREA
  • Analyst Count
  • RLMD 4
  • BREA 0
  • Target Price
  • RLMD $4.25
  • BREA N/A
  • AVG Volume (30 Days)
  • RLMD 4.5M
  • BREA 70.2K
  • Earning Date
  • RLMD 05-12-2025
  • BREA 01-03-2025
  • Dividend Yield
  • RLMD N/A
  • BREA N/A
  • EPS Growth
  • RLMD N/A
  • BREA N/A
  • EPS
  • RLMD N/A
  • BREA N/A
  • Revenue
  • RLMD N/A
  • BREA $2,872,101.00
  • Revenue This Year
  • RLMD N/A
  • BREA N/A
  • Revenue Next Year
  • RLMD N/A
  • BREA N/A
  • P/E Ratio
  • RLMD N/A
  • BREA N/A
  • Revenue Growth
  • RLMD N/A
  • BREA 2338.69
  • 52 Week Low
  • RLMD $0.24
  • BREA $0.50
  • 52 Week High
  • RLMD $4.47
  • BREA $1.95
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 51.73
  • BREA 44.82
  • Support Level
  • RLMD $0.36
  • BREA $0.63
  • Resistance Level
  • RLMD $0.44
  • BREA $0.69
  • Average True Range (ATR)
  • RLMD 0.08
  • BREA 0.04
  • MACD
  • RLMD -0.00
  • BREA -0.01
  • Stochastic Oscillator
  • RLMD 26.98
  • BREA 21.14

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About BREA Brera Holdings PLC

Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.

Share on Social Networks: